Beobachten
- Pressemitteilung BoxID 507332
BRAIN Wins Patent for Biological Wound Conditioning
(PresseBox) (Zwingenberg, )
Today, biotechnology company BRAIN AG announces the granting of a European patent in the field of biotechnological wound conditioning. This new substance patent, registered under the official number EP2245150 B1, was invented by BRAIN within the scope of a BMBF supported research program (FKZ: 0313916). The patent describes a naturally-occurring novel proteolytic enzyme. This biotechnologically produced protein is now used to remove necrotic wound tissue from patients in order to facilitate rapid wound closure. The authority granted the patent application full status as a European patent. The international protection is pending.
Within the framework of the research project "Industrial production processes for novel enzymes and bio-active substances from natural sources: MikroPro", BRAIN has been actively engaged in several subprojects including biological wound conditioning.
This involved isolating and characterising a proteolytic enzyme from the larvae of the Common green bottle fly Lucilia sericata and developing its biotechnological production. This highly potent and specific proteindigesting enzyme (protease) will now be used for conditioning badly healing wounds.
According to the professional magazine "Deutsches Ärzteblatt", about 3 million people in Germany alone suffer from badly or never healing socalled chronic wounds. These include instances of Ulcus cruris, Decubitus or Diabetic foot ulcereration. Today, chronic wounds often require longterm, cost-intensive treatments and amputations are not rare.
At present, one of the difficulties of treating and healing the wound is the complete and pain-free removal of necrotic or devitalized tissue of the wound. This is where BRAIN and their method of enzymatic wound conditioning takes effect. "By identifying this natural functional principle we are able to introduce a completely new method for conditioning wounds", explains Dr. Frank Niehaus, program manager of Enzyme Technologies at BRAIN. "At the moment, we are working together with a number of leading partners to integrate the enzyme into innovative products as fast as possible, obtain international approval and therefore launch the product within the next few months", adds Dr. Michael Krohn, Unit Head BioActives at BRAIN.
"As a SME, the partial funding of this high-risk, highly innovative research project by the BMBF has given us the opportunity to realize project ideas that we would not have been able to pre-finance by ourselves", says Dr. Jürgen Eck, Head of Research at BRAIN AG. "The five year term of the support measure has also given us long-term planning security, which has definitely contributed to the success of the project."
Within the framework of the research project "Industrial production processes for novel enzymes and bio-active substances from natural sources: MikroPro", BRAIN has been actively engaged in several subprojects including biological wound conditioning.
This involved isolating and characterising a proteolytic enzyme from the larvae of the Common green bottle fly Lucilia sericata and developing its biotechnological production. This highly potent and specific proteindigesting enzyme (protease) will now be used for conditioning badly healing wounds.
According to the professional magazine "Deutsches Ärzteblatt", about 3 million people in Germany alone suffer from badly or never healing socalled chronic wounds. These include instances of Ulcus cruris, Decubitus or Diabetic foot ulcereration. Today, chronic wounds often require longterm, cost-intensive treatments and amputations are not rare.
At present, one of the difficulties of treating and healing the wound is the complete and pain-free removal of necrotic or devitalized tissue of the wound. This is where BRAIN and their method of enzymatic wound conditioning takes effect. "By identifying this natural functional principle we are able to introduce a completely new method for conditioning wounds", explains Dr. Frank Niehaus, program manager of Enzyme Technologies at BRAIN. "At the moment, we are working together with a number of leading partners to integrate the enzyme into innovative products as fast as possible, obtain international approval and therefore launch the product within the next few months", adds Dr. Michael Krohn, Unit Head BioActives at BRAIN.
"As a SME, the partial funding of this high-risk, highly innovative research project by the BMBF has given us the opportunity to realize project ideas that we would not have been able to pre-finance by ourselves", says Dr. Jürgen Eck, Head of Research at BRAIN AG. "The five year term of the support measure has also given us long-term planning security, which has definitely contributed to the success of the project."
Über B.R.A.I.N. Biotechnology Research And Information Network AG
BRAIN AG is an industrial "white" biotech company which discovers and develops novel bioactive natural compounds and proprietary enzymes for its partners and customers in the chemical and pharmaceutical industries, as well as the food and cosmetics industries. With its unique approach to the discovery and production of new biological compounds and biocatalysts, the company achieves creative solutions by harnessing nature's untapped biodiversity. Its success is built on its proprietary BioArchive comprising millions of genes, proteins and metabolic pathways from microbial isolates and metagenome libraries. Since its foundation in 1993, BRAIN has entered into over 80 strategic collaborations with nearly all the relevant companies within the chemical industry as e.g. BASF, Ciba, Clariant, Evonik Degussa, DSM, Genencor, Henkel, Nutrinova, RWE, Sandoz, Schering, Südzucker and Symrise, to name but a few. Currently, BRAIN employs 102 highly skilled people.
For their groundbreaking industrial biotechnology activities for a sustainable "biologisation of the chemical industry" using nature's toolbox for industrial processes, BRAIN with its CEO Dr. Holger Zinke received the "Deutschen Umweltpreis 2008" of the "Deutsche Bundesstiftung Umwelt", DBU.
www.brain-biotech.de
Diese Pressemitteilungen könnten Sie auch interessieren
|
Fachtagung 2013 des Gissel Instituts: Aktuelle Themen rund um die Fleischverarbeitung stehen im Blickpunkt
, Biotechnik, Gissel Institut für Bakteriologie und Hygiene
Kaum eine Veranstaltung dürfte geeigneter sein, sich in Sachen Fleisch und Fleischwaren auf den neuesten Stand zu bringen, als die regelmäßige Fachtagung des renommierten...
|
Reading und Imaging vereint im neuen, revolutionären Cytation™3 von BioTek
, Biotechnik, BIOTEK Instruments GmbH
BioTek kündigt stolz die erste Kombination aus Multi-Detektions-Reader mit Hybrid-Technologie und Imaging-System an - den Cytation™3 Multi-Detektions-Reader für...
|
New Roche Award for Antibody-based Cancer Therapy Research
, Biotechnik, Roche Diagnostics GmbH
In a newly created award, pRED's Discovery Oncology unit of Roche (SIX: RO, ROG; OTCQX: RHHBY) in Penzberg, Germany invites European researchers to submit abstracts...
